Gennaro Pagano

Main treatment targets in Parkinson’s disease clinical research 1:25
Main treatment targets in Parkinson’s disease clinical research
Gennaro Pagano • 5 Apr 2023
What is the future of immunotherapy in Parkinson’s disease? 2:03
What is the future of immunotherapy in Parkinson’s disease?
Gennaro Pagano • 5 Apr 2023
Phase I study of selnoflast to slow neurodegeneration in Parkinson’s disease 2:02
Phase I study of selnoflast to slow neurodegeneration in Parkinson’s disease
Gennaro Pagano • 5 Apr 2023
Open label extension of prasinezumab in Parkinson’s disease: 1 year updates 0:55
Open label extension of prasinezumab in Parkinson’s disease: 1 year updates
Gennaro Pagano • 5 Apr 2023
Updates on α-synuclein as a biomarker in Parkinson’s disease 1:10
Updates on α-synuclein as a biomarker in Parkinson’s disease
Gennaro Pagano • 17 Sep 2022
Development of novel trial outcomes in Parkinson’s disease 1:42
Development of novel trial outcomes in Parkinson’s disease
Gennaro Pagano • 17 Sep 2022
Tackling sleep disturbances in Parkinson’s disease 1:33
Tackling sleep disturbances in Parkinson’s disease
Gennaro Pagano • 17 Sep 2022
Prodromal Parkinson’s disease: identification & ethical issues 1:09
Prodromal Parkinson’s disease: identification & ethical issues
Gennaro Pagano • 17 Sep 2022
PADOVA trial: prasinezumab in early Parkinson’s disease 1:34
PADOVA trial: prasinezumab in early Parkinson’s disease
Gennaro Pagano • 17 Sep 2022
Exploratory delayed-start analysis of PASADENA in early-stage Parkinson’s disease 1:43
Exploratory delayed-start analysis of PASADENA in early-stage Parkinson’s disease
Gennaro Pagano • 17 Sep 2022
Alpha-synuclein as a therapeutic target for Parkinson’s disease 2:26
Alpha-synuclein as a therapeutic target for Parkinson’s disease
Gennaro Pagano • 5 Nov 2021
Searching for therapeutic targets for Parkinson’s disease 1:32
Searching for therapeutic targets for Parkinson’s disease
Gennaro Pagano • 5 Nov 2021
Therapeutic approaches to target alpha-synuclein in Parkinson’s disease 1:46
Therapeutic approaches to target alpha-synuclein in Parkinson’s disease
Gennaro Pagano • 5 Nov 2021
Future prospects in Parkinson’s disease 1:00
Future prospects in Parkinson’s disease
Gennaro Pagano • 5 Nov 2021
Prasinezumab: an anti-alpha-synuclein antibody in Parkinson’s disease 1:29
Prasinezumab: an anti-alpha-synuclein antibody in Parkinson’s disease
Gennaro Pagano • 10 Mar 2021
PASADENA trial: prasinezumab in early Parkinson’s disease 1:24
PASADENA trial: prasinezumab in early Parkinson’s disease
Gennaro Pagano • 10 Mar 2021
The content of VJNeurology is intended for healthcare professionals